In a meticulous examination involving 125 participants, the effectiveness of InnerPure, compared to a placebo, was assessed through a range of health parameters. Blood samples, compliance evaluations, and various laboratory tests were conducted, encompassing urine color, pH levels, glucose concentrations, white blood cell counts, and liver enzyme levels. Throughout the study, all subjects exhibited clear-yellow urine, with the live product group displaying an increase in pH levels. Notably, glucose levels in the urine remained within the normal range, and white blood cell counts, as well as liver enzymes, showed normalcy for the live product group. The comprehensive findings underline the positive impact of InnerPure on various health indicators, further supported by the collection of additional insights into participants’ habits and overall well-being.
The Lifeflower® Breviscapini study, a double-blind, randomized, controlled endeavor spanning 90 days, provides compelling insights into the efficacy of this patented ingredient, characterized by its high scutellarin content ranging from 90-98%. The research, incorporating subjects aged 18-70 with specific health criteria, employed a multi-faceted approach involving blood analysis, subjective intakes, and regular phone interactions. Notably, the study demonstrated no significant differences in platelet count, liver enzymes, HbA1c, and calcium levels between the placebo and live product groups. Further enhancing the robustness of the study, the Mini-Mental State Examination (MMSE) was utilized as a cognitive screening tool for participants. These findings underscore the potential health benefits associated with Lifeflower® Breviscapini, offering a promising outlook for individuals seeking holistic well-being.
In addressing the significant burden of preventable cardiovascular diseases (CVD), a study investigated the impact of Farlong NotoGinseng™ on cholesterol and blood pressure. With over 75% of premature CVD deemed preventable by the World Health Organization, hypercholesterolemia and hypertension stand as key modifiable risk factors. The study, conducted on participants with normal to mild hypertension and hypercholesterolemia, revealed that those supplemented with Farlong NotoGinseng™ experienced reductions in CVD risk factors compared to the placebo group. Notably, no significant differences were observed in endothelial function between the two groups. This clinical trial, conducted ethically and in compliance with international guidelines, was supported by Yunnan PanLongYunHai Pharmaceuticals, Ltd. & Longstar Healthpro, Inc. While the findings suggest a positive impact of Farlong NotoGinseng™ on CVD risk factors, further research is warranted for conclusive validation.